Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit?
Novartis cut Lp(a) by 78% with pelacarsen but failed to reduce cardiovascular events, raising the stakes for Amgen and Eli Lilly.
Pharma & Biotech
Pharma & Biotech
Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit?
FDA grants Rybrevant Faspro accelerated approval in advanced head and neck cancer after a 42% response rate, with Phase 3 confirmation still required.
Features & Analysis
Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028?
Samsung Bioepis matched Keytruda in Phase 3, but an earlier FDA filing and Keytruda Qlex complicate the coming biosimilar battle.
Medical Devices & Diagnostics
Siemens Healthineers carves out diagnostics business as Olyrian after Q4 margin falls to 5.4%
Siemens Healthineers is carving out its diagnostics unit as Olyrian after Q4 revenue fell 4.2% and adjusted EBIT margin dropped to 5.4%.
Pharma & Biotech
Johnson & Johnson tests Rybrevant beyond NSCLC as OrigAMI-5 Phase 3 trial advances
Rybrevant Faspro won FDA approval in advanced head and neck cancer after a 42% response rate, taking Johnson & Johnson beyond lung cancer.
Features & Analysis
Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone?
Immunocore reported 70% two-year survival with KIMMTRAK plus brenetafusp, but a randomised Phase 2/3 trial must confirm the signal.
Pharma & Biotech
Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer
Agenus reports durable BOT+BAL survival in refractory MSS colorectal cancer, but a post-hoc Phase 1b analysis still needs randomised confirmation.
Pharma & Biotech
Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands
Camzyos maintained lower heart obstruction through 56 weeks in adolescents as Bristol Myers Squibb expands a $1.15 billion HCM franchise.
Pharma & Biotech
MetaVia’s tiny Phase 1 obesity study just posted 13.5% weight loss and a 68% liver-fat reduction. How much can investors trust yet?
MetaVia’s DA-1726 cut weight 13.5% and liver fat 68% versus placebo at 16 weeks, but the Phase 1 dataset includes just 19 participants.
Features & Analysis
Onkos can put its antibacterial coating on more implants. The FDA claim stops well short of preventing infection
Onkos expands NanoCept across more ELEOS implants, but human evidence that the coating reduces infection risk is still being collected.